<VariationArchive VariationID="852141" VariationName="NM_004937.3(CTNS):c.61_61+2del" VariationType="Deletion" Accession="VCV000852141" Version="10" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-07-29" DateCreated="2020-04-15" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="852736" VariationID="852141">
      <GeneList>
        <Gene Symbol="CTNS" FullName="cystinosin, lysosomal cystine transporter" GeneID="1497" HGNC_ID="HGNC:2518" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3636459" stop="3663103" display_start="3636459" display_stop="3663103" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="3539761" stop="3566396" display_start="3539761" display_stop="3566396" Strand="+" />
          </Location>
          <OMIM>606272</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_004937.3(CTNS):c.61_61+2del</Name>
      <CanonicalSPDI>NC_000017.11:3640264:GTGGT:GT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3640265" stop="3640267" display_start="3640265" display_stop="3640267" variantLength="3" positionVCF="3640264" referenceAlleleVCF="TGTG" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="3543559" stop="3543561" display_start="3543559" display_stop="3543561" variantLength="3" positionVCF="3543558" referenceAlleleVCF="TGTG" alternateAlleleVCF="T" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.3543561_3543563del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.3543561_3543563del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.3640267_3640269del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.3640267_3640269del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012489.2" sequenceAccession="NG_012489" sequenceVersion="2" change="g.8800_8802del">
            <Expression>NG_012489.2:g.8800_8802del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_052852.1" sequenceAccession="NG_052852" sequenceVersion="1" change="g.1056_1058del">
            <Expression>NG_052852.1:g.1056_1058del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001031681.3" sequenceAccession="NM_001031681" sequenceVersion="3" change="c.61_61+2del">
            <Expression>NM_001031681.3:c.61_61+2del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004937.3" sequenceAccession="NM_004937" sequenceVersion="3" change="c.61_61+2del" MANESelect="true">
            <Expression>NM_004937.3:c.61_61+2del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374492.1" sequenceAccession="NM_001374492" sequenceVersion="1" change="c.61_61+2del">
            <Expression>NM_001374492.1:c.61_61+2del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374493.1" sequenceAccession="NM_001374493" sequenceVersion="1" change="c.-296_-296+2del">
            <Expression>NM_001374493.1:c.-296_-296+2del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374495.1" sequenceAccession="NM_001374495" sequenceVersion="1" change="c.-217_-217+2del">
            <Expression>NM_001374495.1:c.-217_-217+2del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374494.1" sequenceAccession="NM_001374494" sequenceVersion="1" change="c.-381+2951_-381+2953del">
            <Expression>NM_001374494.1:c.-381+2951_-381+2953del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374496.1" sequenceAccession="NM_001374496" sequenceVersion="1" change="c.-296+2951_-296+2953del">
            <Expression>NM_001374496.1:c.-296+2951_-296+2953del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004937.2" sequenceAccession="NM_004937" sequenceVersion="2" change="c.61_61+2delGGT">
            <Expression>NM_004937.2:c.61_61+2delGGT</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004937.3" sequenceAccession="NM_004937" sequenceVersion="3" change="c.59_61del" MANESelect="true">
            <Expression>NM_004937.3:c.59_61del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2075652654" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004937.3(CTNS):c.61_61+2del AND Cystinosis" Accession="RCV001585957" Version="9">
        <ClassifiedConditionList TraitSetID="31961">
          <ClassifiedCondition DB="MedGen" ID="C4316899">Cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-08-15" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004937.3(CTNS):c.61_61+2del AND Nephropathic cystinosis" Accession="RCV003467783" Version="1">
        <ClassifiedConditionList TraitSetID="1222">
          <ClassifiedCondition DB="MedGen" ID="C2931187">Nephropathic cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-11-11" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004937.3(CTNS):c.61_61+2del AND multiple conditions" Accession="RCV003768960" Version="1">
        <ClassifiedConditionList TraitSetID="65712">
          <ClassifiedCondition DB="MedGen" ID="C0950123">Inborn genetic diseases</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268626">Juvenile nephropathic cystinosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2931013">Ocular cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-11-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-11-11" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2020-04-15" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12204010</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16199547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27102039</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30554218</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33822926</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9537412</ID>
        </Citation>
        <DescriptionHistory Dated="2022-08-22">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2022-08-07">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2021-09-03">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="65712" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="32761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Inborn genetic diseases</ElementValue>
              </Name>
              <Citation Type="general" Abbrev="Langer et al., 2012">
                <ID Source="PubMed">22947299</ID>
              </Citation>
              <Citation Type="general" Abbrev="SACHDNC, 2013">
                <ID Source="PubMed">23037933</ID>
              </Citation>
              <Citation Type="general" Abbrev="EASAC/FEAM, 2013">
                <ID Source="PubMed">23169492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/P3G/HUGO/PHGF, 2015">
                <ID Source="PubMed">25626707</ID>
              </Citation>
              <Citation Type="general" Abbrev="Alpha-1 Foundation, 2014">
                <ID Source="PubMed">24121147</ID>
              </Citation>
              <Citation Type="general" Abbrev="NBSTRN, 2015">
                <ID Source="PubMed">24394680</ID>
              </Citation>
              <Citation Type="general" Abbrev="EUNENBS, 2014">
                <ID Source="PubMed">23652378</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2014">
                <ID Source="PubMed">23881473</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/ACOG/NSGC/PQF/SMFM, 2015">
                <ID Source="PubMed">25730230</ID>
              </Citation>
              <Citation Type="general" Abbrev="Skirton et al., 2014">
                <ID Source="PubMed">24022298</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23619275</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2019">
                <ID Source="PubMed">31022120</ID>
              </Citation>
              <XRef ID="C0950123" DB="MedGen" />
              <XRef ID="D030342" DB="MeSH" />
            </Trait>
            <Trait ID="1215" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Ocular cystinosis</ElementValue>
                <XRef ID="MONDO:0009064" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosis, ocular nonnephropathic</ElementValue>
                <XRef ID="Cystinosis%2C+Ocular+Nonnephropathic/2080" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosis, adult, nonnephropathic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosis, benign, nonnephropathic</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9756" />
                <XRef ID="9756" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411641" DB="Orphanet" />
              <XRef ID="C2931013" DB="MedGen" />
              <XRef ID="MONDO:0009064" DB="MONDO" />
              <XRef Type="MIM" ID="219750" DB="OMIM" />
            </Trait>
            <Trait ID="1216" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE</ElementValue>
                <XRef Type="MIM" ID="219900" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0016" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0018" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0008" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Juvenile nephropathic cystinosis</ElementValue>
                <XRef ID="Juvenile+nephropathic+cystinosis/8698" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009066" DB="MONDO" />
                <XRef ID="22830006" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17685" />
                <XRef ID="17685" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411634" DB="Orphanet" />
              <XRef ID="C0268626" DB="MedGen" />
              <XRef ID="MONDO:0009066" DB="MONDO" />
              <XRef Type="MIM" ID="219900" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="31961" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6309" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cystinosis</ElementValue>
                <XRef ID="3377" DB="GeneTests" />
                <XRef ID="MONDO:0016239" DB="MONDO" />
                <XRef ID="190681003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystine diathesis</ElementValue>
                <XRef ID="D003554" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystine disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystine storage disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinoses</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6236" />
                <XRef ID="6236" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="C4316899" DB="MedGen" />
              <XRef ID="MONDO:0016239" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1222" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15909" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Abderhalden Lignac Kaufmann disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Abderhalden-Kaufmann-Lignac syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Nephropathic cystinosis</ElementValue>
                <XRef ID="54105" DB="GeneTests" />
                <XRef ID="MONDO:0100151" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lysosomal cystine transport protein, defect of</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosin, defect of</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTNS</ElementValue>
                <XRef ID="GTR000529128" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558532" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="219800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10074" />
                <XRef ID="10074" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411629" DB="Orphanet" />
              <XRef ID="C2931187" DB="MedGen" />
              <XRef ID="MONDO:0100151" DB="MONDO" />
              <XRef Type="MIM" ID="219800" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2386601" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="4934773|MedGen:C0950123;C1857413;C0268626" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001221151" DateUpdated="2024-02-28" DateCreated="2020-04-15" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-11-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16199547</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9537412</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27102039</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12204010</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CTNS are known to be pathogenic (PMID: 9537412, 27102039). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with cystinosis (PMID: 12204010). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 3 of the CTNS gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CTNS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.3543559_3543561del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950123" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1857413" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268626" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3562374" SubmissionDate="2021-09-01" DateLastUpdated="2021-09-08" DateCreated="2021-09-08">
        <ClinVarSubmissionID localKey="NM_004937.2:c.61_61+2delGGT|MedGen:C4316899" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001821269" DateUpdated="2021-09-08" DateCreated="2021-09-08" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12204010</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30554218</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33822926</ID>
          </Citation>
          <Comment>Variant summary: CTNS c.61_61+2delGGT is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the canonical 5' splicing donor site. Three predict the variant strengthens an alternate cryptic exonic 5' splice donor site. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 251378 control chromosomes. c.61_61+2delGGT has been reported in the literature in at-least two individuals affected with Cystinosis and has been subsequently cited by others (example, Kiehntopf_2002, Rohayem_2019, David_2018). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic citing overlapping but not identical evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as likely pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CTNS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004937.2:c.61_61+2delGGT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C4316899" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10303367</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7867332" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_004937.3:c.59_61del|OMIM:219800" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004215231" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004937.3:c.59_61del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219800" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3562374" TraitType="Disease" MappingType="XRef" MappingValue="C4316899" MappingRef="MedGen">
        <MedGen CUI="C4316899" Name="Cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2386601" TraitType="Disease" MappingType="XRef" MappingValue="C0950123" MappingRef="MedGen">
        <MedGen CUI="C0950123" Name="Inborn genetic diseases" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7867332" TraitType="Disease" MappingType="XRef" MappingValue="219800" MappingRef="OMIM">
        <MedGen CUI="C2931187" Name="Nephropathic cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2386601" TraitType="Disease" MappingType="XRef" MappingValue="C1857413" MappingRef="MedGen">
        <MedGen CUI="C2931013" Name="Ocular cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2386601" TraitType="Disease" MappingType="XRef" MappingValue="C0268626" MappingRef="MedGen">
        <MedGen CUI="C0268626" Name="Juvenile nephropathic cystinosis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

